Semax Dosage Chart
Intranasal protocol and 10–14 day course pattern for the Russian-approved cognitive and neuroprotective peptide.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
Semax is a synthetic analog of ACTH (4-10) developed at Russia's Institute of Molecular Genetics. It is approved in Russia for stroke recovery, cognitive impairment, and as a nootropic. Mechanism includes BDNF upregulation and modulation of dopaminergic and serotonergic pathways. It is not FDA-approved in the US.
Semax at a Glance
| Typical dose | 200–600 mcg per nostril (total 400–1,200 mcg per dose) |
|---|---|
| Frequency | 2–3× per day intranasal |
| Course length | 10–14 days, repeated as needed |
| Route | Intranasal spray |
| FDA status | Not FDA-approved (US). Russian-approved for stroke and cognitive indications. |
| Source quality | Russian clinical trial data; limited Western validation. |
Semax Dosing by Use Case
Commonly cited protocols vary by what Semax is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Cognitive support / nootropic | 400–600 mcg total per dose | 2× daily intranasal | 10–14 days, may repeat after 2 weeks off | Most common off-label use case. Pulse-cycle rather than continuous use. |
| Stroke recovery (Russian-labeled) | Higher concentrations per Russian protocol | Multiple times daily under supervision | 10–14 days post-stroke | Russian acute-care protocol — administered in clinical settings only. |
| ADHD / focus support (off-label) | 400 mcg total per dose | Morning + midday intranasal | 2 weeks on, 2 weeks off | Off-label use; not validated in Western trials. |
Stacking Semax
Semax and Selank are sometimes alternated for combined nootropic + anxiolytic support. Co-administration is less common than alternating cycles.
Semax has a clean published Russian safety profile but limited Western validation.
- •Common side effects: mild nasal irritation; rare reports of headache or transient blood pressure changes.
- •Does not produce sedation or stimulant-like dependence in published data.
- •Long-term continuous use beyond labeled course lengths is not well-studied.
- •Not FDA-approved.
- •Pregnancy or breastfeeding
- •Active sinusitis or nasal pathology (avoid intranasal route)
- •Bipolar disorder or active mania (theoretical concern with dopaminergic modulation)
Semax Dosing FAQ
Acute cognitive effects are reported within hours of dosing in published Russian studies. The standard protocol is a 10–14 day course rather than continuous daily use.
No published evidence indicates dependence or withdrawal. The pulsed-course pattern (10–14 days followed by a break) further limits any tolerance development.
Sources
Related Dosage Charts
Want the full Semax guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for Semax therapy.
See Semax guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.